The pes cavovarus foot: Update on current advances

Current Opinion in Orthopaedics

Volumn 18, Issue 2, 2007, Pages 118-123

  Sizensky, Joseph A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Charcot Marie Tooth disease; Pes cavovarus; Pes cavus

Indexed keywords

ASCORBIC ACID; CORTICOSTEROID; NEUROTROPHIN 3;

FOOT DISEASE; FOOT MALFORMATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MOLECULAR GENETICS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PES CAVOVARUS FOOT; PRIORITY JOURNAL; REVIEW;

EID: 33847020436     PISSN: 10419918     EISSN: None     Source Type: Journal    
DOI: 10.1097/BCO.0b013e32805aede4     Document Type: Review

References (48)

1. Brewerton OA, Sandifer PH, Sweetnam DR. 'Idiopathic' pes cavus: an investigation into its aetiology. BMJ 1963; 2:659-661.
2. Manoli A II, Graham B. The subtle cavus foot, the 'underpronator', a review. Foot Ankle Int 2005; 26:256-263. This paper introduces the concept of the subtle cavus foot as a cause for foot and ankle pathology that is frequently missed. It outlines the evaluation and physical findings, the etiology and pathomechanics, the associated pathologic findings, and the treatment of the patient with the subtle cavus foot.
3. Mosca VS. The cavus foot. J Pediatr Orthop 2001; 21:423-424.
4. Beals TC, Manoli A II. The peek-a-boo heel sign in the evaluation of hindfoot varus. Foot 1996; 6:205-206.
5. Coleman SS, Chesnut WJ. A simple test for hindfoot flexibility in the cavovarus foot. Clin Orthop 1977; 123:60-62.
6. Faciszewski T, Burks RT, Manaster BJ. Subtle injuries of the lisfranc joint. J Bone Joint Surg Am 1990; 72:1519-1522.
7. Lloyd-Roberts GC, Swann M, Catterall A. Medial rotational osteotomy for severe residual deformity in clubfoot: a preliminary report on a new method of treatment. J Bone Joint Surg Br 1974; 56:37-43.
8. Berkowitz MJ, Kim DH. Fibular position in relation to ankle stability. Foot Ankle Int 2004; 25:318-321.
9. Fortin PT, Guettler JH, Manoli A II. Idiopathic cavovarus and lateral ankle instability: recognition and treatment implications relating to ankle arthritis. Foot Ankle Int 2002; 23:1031-1037.
10. Larsen E, Angermann P. Association of ankle instability and foot deformity. Acta Orthop Scand 1990; 61:136-139.
11. Brandes CB, Smith RW. Characterization of patients with primary peroneus longus tendinopathy: a review of twenty-two cases. Foot Ankle Int 2000; 21:462-468.
12. Clarke HD, Kitaoka HB, Ehman RL. Peroneal tendon injuries. Foot Ankle Int 1998; 19:280-288.
13. Glasgow MT, Naranja RJ Jr, Glasgow SG, Torg JS. Analysis of failed surgical management of fractures of the base of the fifth metatarsal distal to the tuberosity: the Jones fracture. Foot Ankle Int 1996; 17:449-457.
14. Wright RW, Fischer DA, Shively RA, et al. Refracture of proximal fifth metatarsal fractures after screw fixation in athletes. Am J Sports Med 2000; 28:732-736.
15. Alexander IJ, Johnson KA. Assessment and management of pes cavus in Charcot-Marie-Tooth disease. Clin Orthop 1989; 246:273-281.
16. Paulos L, Coleman SS, Samuelson KM. Pes cavovarus: review of a surgical approach using selective soft-tissue procedures. J Bone Joint Surg Am 1980; 62:942-953.
17. McCluskey WP, Lovell WW, Cummings RJ. The cavovarus foot deformity: etiology and management. Clin Orthop 1989; 247:27-37.
18. Levitt RL, Canale ST, Cooke AJ Jr, Gartland JJ. The role of foot surgery in progressive neuromuscular disorders in children. J Bone Joint Surg Am 1973; 55:1396-1410.
19. Gould N. Surgery in advanced Charcot-Marie-Tooth disease. Foot Ankle 1984; 4:267-273.
20. Docquier P-L, Leemrijse T, Rombouts J-J. Clinical and radiographic features of operatively treated stiff clubfeet after skeletal maturity: etiology of the deformities and how to prevent them. Foot Ankle Int 2006; 27:27-37. This paper reported the persistent radiographic and clinical abnormalities in adults after surgical treatment of clubfoot as a child, including pes cavus and hindfoot varus.
21. Charles YP, Louahem D, Dimeglio A. Cavovarus foot deformity with multiple tarsal coalitions: functional and three-dimensional preoperative assessment. J Foot Ankle Surg 2006; 45:118-126. This paper emphasizes the importance of ruling out tarsal coalition as a cause of pes cavovarus in children.
22. Burns J, Crosbie J, Hunt A, Ouvrier R. The effect of pes cavus on foot pain and plantar pressure. Clin Biomech 2005; 20:877-882. Plantar pressure measurements of patients with pes cavus, regardless of etiology, demonstrated abnormally high pressure-time integrals which are significantly related to foot pain.
23. Redmond A, Burns J, Ouvrier R, et al. An initial appraisal of the validity of a criterion based, observational clinical rating system for foot posture. J Orthopaed Sports Phys Ther 2001; 31:160-164.
24. Yates B, White S. The incidence and risk factors in the development of medial tibial stress syndrome among naval recruits. Am J Sports Med 2004; 32:772-780.
25. Esterman A, Pilotto L. Foot shape and its effect on functioning in Royal Australian Air Force recruits. Part I: Prospective cohort study. Military Med 2005; 170:623-628. This study demonstrated that foot shape has no significant impact on pain, functioning, or risk of injury among military recruits.
26. Cavanagh PR, Rodgers MM. The Arch Index: a useful measure from footprints. J Biomech 1987; 20:547-551.
27. Burns J, Crosbie J, Ouvrier R, Hunt A. Effective orthotic therapy for the painful cavus foot: a randomized controlled trial. J Am Podiatr Med Assoc 2006; 96:205-218. This paper demonstrated that appropriate custom orthotics improved foot pain, functioning, and plantar pressure abnormalities in patients with pes cavus.
28. Shy ME. Charcot-Marie-Tooth disease: an update. Curr Opin Neurol 2004; 17:579-585.
29. Meyer zu Horste G, Prukop T, Nave K-A, Sereda MW. Myelin disorders: causes and perspectives of Charcot-Marie-Tooth neuropathy. J Mol Neurosci 2006; 28:77-88. This paper is an excellent review of the etiology, genetics, and pathophysiology of type I CMT disease, most often due to a duplication on chromosome 17, causing overexpression of peripheral myelin protein 22. Further, it discusses several possible experimental therapeutic approaches, including the use of progesterone receptor antagonists and ascorbic acid, to reduce clinical severity.
30. Nicholson GA. The dominantly inherited motor and sensory neuropathies: clinical and molecular advances. Muscle Nerve 2006; 33:589-597. This is an excellent review of the genetics of the dominantly inherited forms of CMT disease.
31. Zhou L, Griffin JW. Demyelinating neuropathies. Curr Opin Neurol 2003; 16:307-313.
32. Boerkoel CF, Takashima H, Garcia CA, et al. Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann Neurol 2002; 51:190-201.
33. Zuchner S, Mersiyanova IV, Muglia M, et al. Mutations in the mitochondrial GTPase mitofusin 2 causes Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004; 36:449-451.
34. Lawson VH, Graham BV, Flanigan KM. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology 2005; 65:197-204. This paper demonstrated that the majority of cases of type 2A CMT disease are due to mutations in the mitofusin 2 gene which encodes for a mitochondrial GTPase. It also describes the clinical and electrophysiologic features of the disease.
35. Verhoeven K, Claeys KG, Zuchner S, et al. MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain 2006; 129 (Pt 8):2093-2102. This paper confirmed the finding that 33% of patients with type 2 CMT disease have a mutation in the mitofusin 2 gene. The clinical and electrophysiologic findings are reviewed. Sural nerve biopsies demonstrated loss of myelinated nerve fibers as well as degenerative mitochondrial changes.
36. Frank S. Dysregulation of mitochondrial fusion and fission: an emerging concept in neurodegeneration. Acta Neuropathol 2006; 111:93-100. This is an excellent review of the role of mitochondrial dysfunction in the pathogenesis of neurodegenerative disorders. The author speculates that specific gene mutations may alter balance between mitochondrial fusion and fission, leading to these disorders.
37. Tang B, Liu X, Zhao G, et al. Mutation analysis of the small heat shock protein 27 gene in Chinese patients with Charcot-Marie-Tooth disease. Arch Neurol 2005; 62:1201-1207. This paper reports the finding that the mutations in the small heat shock protein 27 gene can cause some cases of type 2 CMT disease.
38. Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004; 10:396-401.
39. Sahenk Z, Nagaraja HN, McCracken BS, et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 2005; 65:681-689. In this study, mice with a peripheral myelin protein 22 mutation (a common cause of CMT disease, which is characterized by peripheral axonal degeneration) were treated with either neurotrophin-3 or sham treatment (control) and the numbers of myelinated nerve fibers and Schwann cells were quantified after treatment. The authors found that the neurotrophin-3 augments nerve regeneration and noted slight (but not statistically significant) improvement in functional performance.
40. Carvalho AAS, Vital A, Ferrer X, et al. Charcot-Marie-Tooth disease type 1A: clinicopathological correlations in 24 patients. J Periph Nerv Syst 2005; 10:85-92. This paper demonstrates that some patients with atypical CMT disease type IA demonstrated features of macrophage-associated demyelination. This may be important since these patients may respond to corticosteroid therapy.
41. Alexander IA. Pes Cavus. In: Nunley JA, Pfeffer GB, Sanders RW, Trepman E, editors. Advanced reconstruction foot and ankle, 1st ed Chicago: American Academy of Orthopaedic Surgeons; 2004. pp. 495-502.
42. Gallardo E, Garcia A, Combarros O, Berciano J. Charcot-Marie-Tooth disease type 1A duplication: spectrum of clinical and magnetic resonance imaging features in leg and foot muscles. Brain 2006; 129 (Pt 2):426-437. The authors correlated the clinical and electrophysiologic findings with the MRI findings in 11 patients with CMT type IA patients. They found that in patients with minimal clinical and electrophysiologic disease the MRI demonstrated fatty infiltration of the foot intrinsics with involvement of the proximal leg muscles only with mild or moderate disease. These findings imply that, early on, deformity can be caused entirely by intrinsic muscle involvement alone.
43. Burns J, Redmond A, Ouvrier R, Crosbie J. Quantification of muscle strength and imbalance in neurogenic pes cavus, compared to healthy controls, using hand-held dynamometry. Foot Ankle Int 2005; 26:540-544. This paper demonstrated that hand-held dynamometry is an objective and reliable tool to assess muscle strength and imbalance in patients with neurogenic per cavus.
44. Wicart P, Seringe R. Plantar opening-wedge osteotomy of cuneiform bones combined with selective plantar release and Dwyer osteotomy for pes cavovarus in children. J Pediatr Orthop 2006; 26:100-108. These authors present a unique surgical approach to the child with pes cavovarus including a plantar opening-wedge osteotomy of the three cuneiforms and plantar soft tissue release with or without a Dwyer calcaneal osteotomy and other procedures as necessary, including an Achilles tendon lengthening, lateral column shortening, first metatarsal osteotomy, and medial soft tissue release. The deformity was corrected in 74% but 36% were unsatisfied with the procedure.
45. Azmaipairashvili Z, Riddle EC, Scavina M, Kumar SJ. Correction of cavovarus foot deformity in Charcot-Marie-Tooth disease. J Pediatr Orthop 2005; 25:360-365. The authors describe the Coleman block view, a novel radiologic method of assessing the flexibility of the hindfoot in patients with pes cavovarus. The authors found this test to be useful in the evaluation of these patients and in choosing the optimal surgical approach to treatment.
46. Vinci P, Serrao M, Millul A, et al. Quality of life in patients with Charcot-Marie-Tooth disease. Neurology 2005; 65:922-924. These authors evaluated the quality of life of patients with CMT disease using the SF-36 questionnaire and found the scores were lower in nonworking versus working, female versus male, and older versus younger patients but not between patients with the axonal versus the demyelinating forms or between patients who had had surgery versus those that did not.
47. Shy ME, Rose MR. Charcot-Marie-Tooth disease impairs quality of life: why? And how do we improve it? Neurology 2005; 65:790-791. This review paper points out that quality of life outcomes do not invariably correlate with disease severity because it does not take into account the discrepancy between patients' perceptions of their ideal state versus their real state. The observed differences noted may be due to overlying mental function disorders or other psychological factors, including depression, independent of the effect of the disease.
48. Shy ME, Blake J, Krajewski K, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005; 64:1209-1214. This paper demonstrates the reliability and validity of a novel method for quantifying disability in patients with CMT disease, the CMTNS. This can also be used as an endpoint for longitudinal studies and clinical trials of CMT patients.